Spherusol Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The spherusol market research report is one of a series of new reports that provides spherusol market statistics, including the spherusol industry's global market size, regional shares, competitors with a spherusol market share, detailed spherusol market segments, market trends and opportunities, and any further data you may need to thrive in the spherusol industry. This spherusol market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to growing awareness of coccidioidomycosis, expanding testing in non-endemic regions, supportive healthcare policies, increasing funding for fungal disease research, rising demand for point-of-care diagnostics, and growing prevalence of respiratory diseases. Major trends in the forecast period include advancements in diagnostic tools, integration with electronic health records for better patient tracking, advancements in diagnostic technologies, development of faster testing procedures, adoption of telemedicine, and innovation in formulations.

The increasing incidence of coccidioidomycosis (valley fever) is expected to drive the growth of the Spherusol market in the future. Coccidioidomycosis is a fungal infection caused by the Coccidioides fungus, typically found in dry, sandy soils. It primarily affects the lungs and can spread to other parts of the body through inhaling fungal spores. The rise in cases is attributed to factors such as climate change, which creates warmer and drier conditions ideal for the fungus, and population growth in regions where the disease is endemic, increasing human exposure. Spherusol plays a key role in diagnosing the disease through a skin test that detects hypersensitivity to Coccidioides immitis. The test measures the skin’s reaction 48 hours after injection to confirm prior exposure to the fungus. For example, in April 2024, the Centers for Disease Control and Prevention (CDC) reported 17,612 cases of valley fever in 2022, with an estimated 10,000 to 20,000 cases annually, most commonly affecting individuals over 60 years old. As the prevalence of coccidioidomycosis rises, so will the demand for Spherusol.

The growing popularity of outdoor activities is also expected to contribute to the expansion of the Spherusol market. Outdoor activities, which include recreational or physical pursuits in open spaces or natural environments, have been increasing as people prioritize exercise, mental well-being, and a break from technology, influenced by health benefits and social media trends. However, exposure to outdoor allergens is also rising, and Spherusol helps manage these reactions by desensitizing the immune system. According to the 2023 Outdoor Participation Trend report by the Outdoor Industry Association (OIA), the number of outdoor recreation participants grew by 2.3% in 2022, reaching 168.1 million people, up from 164.2 million in 2021. This surge in outdoor activity is expected to further fuel the demand for Spherusol.

The increase in the aging population is anticipated to drive the growth of the Spherusol market as well. As people age, they experience various physiological changes, such as reduced skin elasticity, wrinkles, and other age-related conditions. This demographic shift is largely due to advances in healthcare, better living standards, and improved medical treatments that extend life expectancy. Spherusol can be used to manage conditions such as generalized pustular psoriasis in older adults, providing an effective treatment option for this group. The Population Reference Bureau projected in January 2024 that the number of Americans aged 65 and older would grow from 58 million in 2022 to 82 million by 2050, an increase of 47%. This will raise the proportion of people aged 65 and above in the U.S. population from 17% to 23%. As the aging population grows, so too will the demand for treatments such as Spherusol.

The key company operating in the spherusol market is Nielsen Biosciences Inc.

North America was the largest region in the spherusol market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in spherusol report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Spherusol market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Spherusol is a diagnostic skin test designed to detect delayed-type hypersensitivity (DTH) reactions caused by exposure to Coccidioides fungi, which are responsible for valley fever (coccidioidomycosis). The test assesses past infections and immune responses, but it is not intended for diagnosing active infections.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary indications for spherusol include pain management, infection control, neurological disorders, and oncology. In pain management, various treatments and diagnostic tools are used to relieve chronic pain, which may involve medications, physical therapy, and specific diagnostic tests. For Spherusol, it is particularly used when pain is associated with coccidioidomycosis, a fungal infection that can cause severe symptoms such as chest, joint, and muscle pain. It is distributed through hospital pharmacies, retail pharmacies, and online platforms, and is primarily utilized by hospitals, diagnostic laboratories, and research institutions.

The spherusol market consists of sales of skin test antigens, which include sterile solutions and injections. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.